Clinical Trial Update: RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update for RN1201 injection in relapsed/refractory CD19+/BCMA+ hematologic malignancies, currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Hematologic Malignancies
• Mature B-cell Lymphoma
• Multiple Myeloma
• Plasmablastic Lymphoma

Drugs mentioned

• RN1201

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Relapsed or Refractory B-cell Hematologic Malignancies, B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Status: NOT_YET_RECRUITING